These trials (4 in phase 1, 8 in phase 2, 9 in phase 3) are using IDO inhibitors (Epacadostat, Indoximolod, GDC-0919; etc.)in combination with immunotherapy (anti-PD-1: nivolumab or pembrolizumab, anti-CTLA4: ipilimumab, etc.)or targeted chemotherapies on different types of cancer (lung, breast, pancreas, etc.). The gene discussed is IDO1; the disease is cancer.